Literature DB >> 7139596

Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation.

I Tannock.   

Abstract

I have assessed the relative sensitivity of aerobic and hypoxic cells to Adriamycin (ADR) and cyclophosphamide (CY) in the drug-sensitive murine 16/C tumor. The end point used was tumor response to subsequent radiation given under aerobic or acutely hypoxic conditions. Delay in tumor growth following 15 gray radiation alone to approximately 0.4 g tumors was about 3 days longer after aerobic than after hypoxic radiation. Prior treatment with CY had little effect on this difference, implying little selectivity of CY for killing aerobic or hypoxic cells, and the effects of CY and radiation were additive. Treatment with ADR abolished the difference in response to aerobic and hypoxic radiation given from 0.5 to 2 hr after the drug, suggesting that most of the cells which survived treatment with ADR were hypoxic. Difference in response to aerobic and hypoxic radiation at 6 to 24 hr after ADR was equal to or greater than that in non-drug-treated mice, implying rapid reoxygenation after ADR. Experiments on small, nonpalpable tumors with a low proportion of hypoxic cells showed that ADR was slightly more effective than against larger tumors and that some aerobic cells were spared by the drug when the hypoxic fraction was small. Misonidazole is known to be selectively toxic for hypoxic cells, and a high dose of misonidazole gave a small increase in antitumor effects of ADR without increased toxicity. My results suggest that ADR (but not CY) may spare hypoxic cells in a solid tumor and are consistent with limited diffusion of ADR from tumor blood vessels.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7139596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

2.  Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Authors:  Sant P Chawla; Lee D Cranmer; Brian A Van Tine; Damon R Reed; Scott H Okuno; James E Butrynski; Douglas R Adkins; Andrew E Hendifar; Stew Kroll; Kristen N Ganjoo
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

3.  The influence of Fluosol-DA and carbogen breathing on the antitumor effects of cyclophosphamide in vivo.

Authors:  G E Kim; C W Song
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Anti-angiogenic therapy induces integrin-linked kinase 1 up-regulation in a mouse model of glioblastoma.

Authors:  Chiara Verpelli; Giulio Bertani; Valentina Cea; Monica Patti; Andreas Bikfalvi; Lorenzo Bello; Carlo Sala
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

5.  Toxicity of 5-fluorouracil for aerobic and hypoxic cells in two murine tumours.

Authors:  I F Tannock
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

8.  Differential protective effects of varying degrees of hypoxia on the cytotoxicities of etoposide and bleomycin.

Authors:  T Yamauchi; T A Raffin; P Yang; B I Sikic
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Using optical spectroscopy to longitudinally monitor physiological changes within solid tumors.

Authors:  Karthik Vishwanath; Hong Yuan; William T Barry; Mark W Dewhirst; Nimmi Ramanujam
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

Review 10.  A chemical perspective on the anthracycline antitumor antibiotics.

Authors:  B R Abdella; J Fisher
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.